Doha – Novartis Pharma Maroc has appointed Yahya Abdallah as country president for its Morocco, Tunisia, and Algeria (MTA) regional operations. Based in Casablanca, Abdallah will oversee the company’s strategic initiatives across these three North African markets.
The appointment, according to the company, coincides with a time when Morocco is implementing major healthcare reforms aimed at ensuring universal access to medical services.
Abdallah brings over 20 years of pharmaceutical industry experience to the role, including 14 years at Novartis where he has held various leadership positions.
In his most recent role, Abdallah served as Head of Business Excellence and Execution for the Levant region from October 2022 until he took the helm of his current position.
His previous positions at Novartis included Country Head for Jordan and Palestine, Franchise Head for Immunology & Dermatology in the Levant, and various other regional management roles.
“I am deeply honored to lead a team so committed and passionate about improving lives,” Abdallah said in a press release.
“Together, we will drive meaningful transformation in the healthcare landscape across the region, always keeping patients at the heart of our mission and introducing innovations that truly make a difference,” he added.
Abdallah’s career in pharmaceuticals began at Pfizer in 2003, followed by roles at Hikma Pharmaceuticals and Ferring Pharmaceuticals before joining Novartis in 2011.
He holds an executive leadership program certificate from INSEAD and graduated from Jami’at Al-Ulum wa Al-Tiknolojia Al-Urdunia in 2003.
Novartis, headquartered in Basel, Switzerland, ranks among the world’s largest pharmaceutical companies, with reported revenues of $50.32 billion in 2024.
The company employs over 75,000 people globally and maintains its position as Europe’s third most valuable pharmaceutical company, after Novo Nordisk and Roche.
The appointment, according to the company, coincides with a time when Morocco is implementing major healthcare reforms aimed at ensuring universal access to medical services.
Abdallah brings over 20 years of pharmaceutical industry experience to the role, including 14 years at Novartis where he has held various leadership positions.
In his most recent role, Abdallah served as Head of Business Excellence and Execution for the Levant region from October 2022 until he took the helm of his current position.
His previous positions at Novartis included Country Head for Jordan and Palestine, Franchise Head for Immunology & Dermatology in the Levant, and various other regional management roles.
“I am deeply honored to lead a team so committed and passionate about improving lives,” Abdallah said in a press release.
“Together, we will drive meaningful transformation in the healthcare landscape across the region, always keeping patients at the heart of our mission and introducing innovations that truly make a difference,” he added.
Abdallah’s career in pharmaceuticals began at Pfizer in 2003, followed by roles at Hikma Pharmaceuticals and Ferring Pharmaceuticals before joining Novartis in 2011.
He holds an executive leadership program certificate from INSEAD and graduated from Jami’at Al-Ulum wa Al-Tiknolojia Al-Urdunia in 2003.
Novartis, headquartered in Basel, Switzerland, ranks among the world’s largest pharmaceutical companies, with reported revenues of $50.32 billion in 2024.
The company employs over 75,000 people globally and maintains its position as Europe’s third most valuable pharmaceutical company, after Novo Nordisk and Roche.
